CN103242273B - 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 - Google Patents

2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 Download PDF

Info

Publication number
CN103242273B
CN103242273B CN201210028895.0A CN201210028895A CN103242273B CN 103242273 B CN103242273 B CN 103242273B CN 201210028895 A CN201210028895 A CN 201210028895A CN 103242273 B CN103242273 B CN 103242273B
Authority
CN
China
Prior art keywords
compound
methyl
preparation
esi
pharmacologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210028895.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103242273A (zh
Inventor
杨春皓
缪泽鸿
丁健
王猛
贺金雪
谭村
陈奕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukang (shanghai) Health Technology Co Ltd
Shanghai Institute of Materia Medica
Original Assignee
Shanghai Institute of Materia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201210028895.0A priority Critical patent/CN103242273B/zh
Application filed by Shanghai Institute of Materia Medica filed Critical Shanghai Institute of Materia Medica
Priority to CA2863988A priority patent/CA2863988C/en
Priority to JP2014555927A priority patent/JP5926821B2/ja
Priority to PCT/CN2013/070410 priority patent/WO2013117120A1/zh
Priority to BR112014019402-5A priority patent/BR112014019402B1/pt
Priority to EP13746724.7A priority patent/EP2813495B1/en
Priority to US14/375,742 priority patent/US9533965B2/en
Priority to RU2014132159/04A priority patent/RU2583900C2/ru
Publication of CN103242273A publication Critical patent/CN103242273A/zh
Application granted granted Critical
Publication of CN103242273B publication Critical patent/CN103242273B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201210028895.0A 2012-02-09 2012-02-09 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 Active CN103242273B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201210028895.0A CN103242273B (zh) 2012-02-09 2012-02-09 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
JP2014555927A JP5926821B2 (ja) 2012-02-09 2013-01-14 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途
PCT/CN2013/070410 WO2013117120A1 (zh) 2012-02-09 2013-01-14 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
BR112014019402-5A BR112014019402B1 (pt) 2012-02-09 2013-01-14 Composto 2-aril-benzofuran-7-carboxamida, ou sal farmacologicamente aceitável do mesmo e método para a preparação do composto
CA2863988A CA2863988C (en) 2012-02-09 2013-01-14 2-aryl/heteroarylbenzofuran-7-formamide compounds, preparation method and use thereof
EP13746724.7A EP2813495B1 (en) 2012-02-09 2013-01-14 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof
US14/375,742 US9533965B2 (en) 2012-02-09 2013-01-14 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof
RU2014132159/04A RU2583900C2 (ru) 2012-02-09 2013-01-14 Соединения 2-арилбензофуран-7-формамида, способ их получения и применение

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210028895.0A CN103242273B (zh) 2012-02-09 2012-02-09 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN103242273A CN103242273A (zh) 2013-08-14
CN103242273B true CN103242273B (zh) 2015-06-03

Family

ID=48922178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210028895.0A Active CN103242273B (zh) 2012-02-09 2012-02-09 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Country Status (8)

Country Link
US (1) US9533965B2 (cg-RX-API-DMAC7.html)
EP (1) EP2813495B1 (cg-RX-API-DMAC7.html)
JP (1) JP5926821B2 (cg-RX-API-DMAC7.html)
CN (1) CN103242273B (cg-RX-API-DMAC7.html)
BR (1) BR112014019402B1 (cg-RX-API-DMAC7.html)
CA (1) CA2863988C (cg-RX-API-DMAC7.html)
RU (1) RU2583900C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013117120A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024187321A1 (zh) 2023-03-10 2024-09-19 甫康(上海)健康科技有限责任公司 含有egfr抑制剂的药物组合物及其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
MX2015006780A (es) 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
CN105272936B (zh) * 2014-05-27 2019-05-17 中国科学院上海药物研究所 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途
CN109134409B (zh) 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康(上海)健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029384A1 (de) * 1998-11-17 2000-05-25 Basf Aktiengesellschaft 2-phenylbenzimidazole und 2-phenylindole, deren herstellung und anwendung
US7087637B2 (en) * 2000-05-11 2006-08-08 Basf Ag Substituted indoles which are PARP inhibitors
CN101641014A (zh) * 2006-12-28 2010-02-03 艾博特公司 聚(adp-核糖)聚合酶抑制剂
WO2010054278A2 (en) * 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87451A0 (en) 1987-09-04 1989-01-31 Tanabe Seiyaku Co Benzofuran derivatives,their preparation and pharmaceutical compositions containing them
JP2002515488A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びparp活性の抑制方法
TR200101239T2 (tr) * 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
DE10351315A1 (de) 2003-10-31 2005-06-16 Aventis Pharma Deutschland Gmbh 2-Phenyl-benzofuran-Derivate, Verfahren zur ihrer Herstellung und ihre Verwendung
CA2580833C (en) * 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
JP5162465B2 (ja) * 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
JP2010518146A (ja) 2007-02-16 2010-05-27 グラクソ グループ リミテッド ベンゾフラン化合物
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
CN101998959B (zh) * 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
GB0806656D0 (en) 2008-04-11 2008-05-14 Karobio Ab Novel estrogen receptor ligands
US8476309B2 (en) 2009-08-20 2013-07-02 The University Of Tennessee Research Foundation Benzofuran cannabinoid compounds and related methods of use
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029384A1 (de) * 1998-11-17 2000-05-25 Basf Aktiengesellschaft 2-phenylbenzimidazole und 2-phenylindole, deren herstellung und anwendung
US7087637B2 (en) * 2000-05-11 2006-08-08 Basf Ag Substituted indoles which are PARP inhibitors
CN101641014A (zh) * 2006-12-28 2010-02-03 艾博特公司 聚(adp-核糖)聚合酶抑制剂
WO2010054278A2 (en) * 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024187321A1 (zh) 2023-03-10 2024-09-19 甫康(上海)健康科技有限责任公司 含有egfr抑制剂的药物组合物及其制备方法和应用

Also Published As

Publication number Publication date
RU2014132159A (ru) 2016-03-27
BR112014019402A8 (pt) 2017-07-11
US20150018542A1 (en) 2015-01-15
BR112014019402A2 (cg-RX-API-DMAC7.html) 2017-06-20
WO2013117120A1 (zh) 2013-08-15
RU2583900C2 (ru) 2016-05-10
BR112014019402B1 (pt) 2020-12-15
EP2813495A4 (en) 2015-06-17
JP5926821B2 (ja) 2016-05-25
JP2015511942A (ja) 2015-04-23
EP2813495B1 (en) 2016-09-28
CA2863988A1 (en) 2013-08-15
CA2863988C (en) 2016-03-22
US9533965B2 (en) 2017-01-03
CN103242273A (zh) 2013-08-14
EP2813495A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
CN103242273A (zh) 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN105142634B (zh) 包含Src同源-2结构域的致癌性蛋白酪氨酸磷酸酶-2(SHP2)的基于羟基吲哚羧酸的抑制剂
AU742641B2 (en) Novel tricyclic compound
CN101687798B (zh) 制备用于调节激酶级联的组合物的过程及其使用方法
CN104169260A (zh) 新三嗪衍生物
CN115768761B (zh) 新颖苯并咪唑衍生物
EP3480199A1 (en) Imidazopyridinamine phenyl derivative and use thereof
TW200812970A (en) Inhibitors of AKT (protein kinase B)
CN102452988B (zh) 一种喹唑啉衍生物及其制备方法
WO2022107745A1 (ja) Covid-19の治療剤又は予防剤
CN108069954B (zh) 含no供体的喹唑啉酮化合物
Wang et al. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of colorectal cancer
CN109748914A (zh) 吡啶并嘧啶类化合物及其应用
TW565559B (en) Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them
CN109096272A (zh) 一种具有抗肿瘤活性的吲哚异羟肟酸类化合物及其应用
EP3684354B1 (en) Xpa inhibitor compounds and their use
CN102212032B (zh) 一种5-羟基喹诺酮类衍生物及其制备方法和用途
WO2010062221A1 (ru) Замещенные 2-(5-гидpokcи-2-metил-1н-иhдoл-3-ил)уkcуchыe кислоты и их эфиры и их применение для лечения вирусных заболеваний
CN110903224A (zh) 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途
CN111018686B (zh) 6-苄亚基-2-芳基乙炔基环己烯酮衍生物及其制备方法和医药用途
CN115322120A (zh) 一类小分子化合物及在制备治疗dhodh介导疾病药物中的用途
CN119528929B (zh) 鬼臼毒素三氮唑醚衍生物及其制备方法和应用
CN115260081B (zh) 一种磺酰胺类吲哚芳基砜衍生物及其制备方法与应用
WO2019234740A1 (en) Mitogen-activated protein kinase kinase 7 inhibitors
CN108129486A (zh) 嘧啶酮衍生物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20181102

Address after: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Co-patentee after: Fukang (Shanghai) Health Technology Co., Ltd.

Patentee after: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Address before: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

TR01 Transfer of patent right